Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

Figures & data

Table 1. Main results of tafasitamab trials in DLBCL.

Trial	NCT	Phase	Setting	Regimen	ORR	PFS
First-MIND^Citation28	NCT04134936	Ib	1 L DLBCL	6 × q21 tafa +R-CHOP ± lenalidomide (25 mg/day, days 1–10)	75.8% (CR 72.7%) in arm T and 81.8% (CR 66.7%) in arm T/L;
MOR208C201^Citation29	NCT01685008	II	R/R NHL	Tafa weekly C1–3; extended treatment available for responding patients	26% in DLBCL cohort	median PFS 2.7 months (95% CI 2.1–15.4)
L-MIND^Citation32	NCT02399085	II	R/R DLBCL	12 × q28 cycles of tafa + lenalidomide (25 mg/day, Days 1–21), then tafa monotherapy	ORR was 57.5%, with CR of 41.3%	Median PFS 11.6 months (95% CI, 5.7–45.7)

Legend: DLBCL: diffuse large B cell Lymphoma, R/R: relapsed and refractory; NHL: non Hodgkin lymphoma; ORR: objective response rate, PFS: progression free survival.

Table 2. Ongoing trial tafasitamab-based in DLBCL.

NCT	Phase	Setting	Regimen	Status (Sep 2023)
NCT05626322	Ib, II	R/R DLBCL	Maplirpacept (anti CD47) weekly C1-C3 then every 2 weeks. Tafa weekly C1-C3 and then every 2 weeks. Lenalidomide d1-d21, q28 up to C12	Recruiting
NCT04661007	Ib, II	R/R DLBCL	Tafa alone, tafa + lenalidomide, tafa + parsaclisib and tafa + lenalidomide in combination with R-CHOP in Japanese participants	Recruiting
NCT04974216	II	1 L DLBCL elderly pts	12 cycles q28. From C1 to C6: rituximab + tafa + lenalidomide and from C7 to C12: tafa and lenalidomide	Recruiting
NCT04824092	II	1 L DLBCL (high, intermediate risk)	6 × q21 R-CHOP ± lenalidomide (25 mg/day, days 1–10) + tafa weekly	Active, not recruiting
NCT02763319	II/III	R/R DLBCL	Tafa + bendamustine vs R-Bendamustine	Active, not recruiting
NCT04978584	II	1 L non-GCB DLBCL	4 × q21 R (D1)+lenalidomide (d1–10) + acalabrutinib (d1-d21) + tafa weekly vs 6 × q21 R-CHOP (D1) + lenalidomide (d1–10)+acalabrutinib (d1-d21) + tafa weekly	Recruiting

Legend: DLBCL: diffuse large B cell Lymphoma, Non-GCB: non germinal center B, R/R: relapsed and refractory; pts: patients.

Mougiakakos D, Voelkl S, Bach C, Stoll A, Bitterer K, Beier F, Endell J, Boxhammer R, Bittenbring JT, Mackensen A, et al. Mechanistic characterization of tafasitamab-mediated antibody-dependent cellular phagocytosis alone or in combination with lenalidomide. Blood. 2019;134(Supplement_1):4064–4064. doi:10.1182/blood-2019-124886.

 Google Scholar

Woyach JA, Awan F, Flinn IW, Berdeja, J.G., Wiley, E., Mansoor, S., Huang, Y., Lozanski, G., Foster, P.A. and Byrd, J.C. et al. Dec 4 2014. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 124(24):3553–60. doi:10.1182/blood-2014-08-593269.

 PubMed Web of Science ®Google Scholar

Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann Oncol. May 1 2018;29(5):1266–1272. doi:10.1093/annonc/mdy056.

 PubMed Web of Science ®Google Scholar